Drugs / SSGJ-706
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06533605 | Aug 2024 → Jul 2025 | neoplasm | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07233850 | Nov 2025 → Dec 2026 expected | colorectal cancer, esophageal cancer, gastroesophageal junction adenocarcinoma, pancreatic ductal adenocarcinoma | Shenyang Sunshine Pharmaceutical Co., LTD. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07171606 | Oct 2025 → Aug 2026 overdue | — | Shenyang Sunshine Pharmaceutical Co., LTD. | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SSGJ-706 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06533605 ↗ |